沙库巴曲缬沙坦治疗原发性高血压并射血分数保留心力衰竭的疗效

Abstract
Figure/Table
References
Related Citation (9)

Download: PDF (664 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the curative effect and prognosis of sakubitril valsartan in treating patients with heart failure with preserved ejection fraction (HFpEF) and primary hypertension.Methods Sixty-three patients with primary hypertension with HFpEFwere chosen from Xinjiang Provincial Corps Hospital between January 2018 and June 2020 and divided into the experimental group (n=32) and control group (n=31). The experimental group was given sakubitril valsartan, while the control group was treated with valsartan. Both groups were followed up for 3 months before the level of N-terminal pro-brain natriuretic peptide (NT-proBNP), NYHA classification of heart function and 6-minute walk test (6MWT), blood pressure, left atrial diameter (LAD), E/A ratio, left ventricular end-diastolic diameter (LVEDD), and left ventricular ejection fraction (LVEF) were observed.Results The distance of 6MWT in the experimental group was improved more significantly than that in the control group [(516.8±47.5)m vs. (425.7±68.5)m], so was the ratio of E/A[(0.97±0.15) vs. (0.87±0.16)].The level of NT-proBNP in the experimental group was lower than that of the control group (2528.3±761.3)pg/ml vs. (4897.8±966.3) pg/ml. The rate of cardiac function improvement in the treatment group was 87.5%, which was significantly higher than that in the control group (61.2%). The level of blood pressure in both groups was significantly decreased, but there was no significant difference between the two groups after treatment. LVEF, LAD and LVEDD were not statistically significant between the two groups after treatment.Conclusions Sakubitril valsartan can effectively relieve clinical symptoms, improve the distance of 6MWT and E/A ratio, and reduce NT-proBNP levels in patients of primary hypertension with HFpEF.

Key words： primary hypertension heart failure with preserved ejection fraction sakubitril valsartan

Received: 27 July 2020

ZTFLH:

R541.61

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2020/V31/I12/1017

[1]	王洁好,华琦.左心室射血分数保留的心力衰竭研究进展[J].中华老年心脑血管病杂志,2016,18(7):766-769.
[2]	中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志,2018,46(10):760-789.
[3]	Ponikowski P, Voors A A, Anker S D, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)[J]. Eur J Heart Fail, 2016, 18(8): 891-975.
[4]	中国高血压防治指南修订委员会,高血压联盟(中国),中华医学会心血管病学分会,中国医师协会高血压专业委员会,中国医疗保健国际交流促进会高血压分会,中国老年医学学会高血压分会. 中国高血压防治指南(2018年修订版)[J]. 中国心血管病杂志,2019,24(1):24-56.
[5]	周华,王丽萍. 沙库巴曲缬沙坦钠片治疗左心室射血分数保留心力衰竭的疗效分析[J]. 现代实用医学,2020,32(5):484-485.
[6]	Buggey J,Alenezi F,Yoon H J,et al. Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization[J]. ESC Heart Fail, 2017,4( 4):432-439.
[7]	Dunlay S M,Roger V L,Redfield M. Epidemiology of heart failure with preserved ejection fraction[J].Nat Rev Cardiol, 2017, 14(10):591-602.
[8]	洪华山.老年慢性心力衰竭的药物和非药物治疗现状[J].中华老年心脑血管病杂志,2015,17(2):785-788.
[9]	Catena C,Colussi G,Brosolo G,et al. Aldosterone and left ventricular remodeling[J], Horm Metab Res,2015,47( 13) :981-986.
[10]	Te Riet L,van Esch J H,Roks A J,et al.Hypertension: renin-angiotensin-aldosterone system alterations[J]. Circ Res, 2015, 116( 6) :960-975.
[11]	黄明辉,胡钰,汤玲玲, 等. 高血压在射血分数保留的心力衰竭发展中的作用[J].心血管病学进展, 2019,40(2):294-296.
[12]	Teng T K, Tay W T, Dahlstrom U, et al.Different relationships between pulse pressure and mortality in heart failure with reduced,midrange and preserved ejection fraction[J].Int J Cardiol,2018,25(4):203-209.
[13]	Sartipy U,Dahlstrm U,Fu M,et al. Atrial fibrillation in heart failure with preserved,midrange,and reduced ejection fraction[J].JACC Heart Fail,2017,5(8):565-574.
[14]	Welsh P, Kou L, Yu C, et al. Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: REDHF study [J]. Eur J Heart Fail, 2018, 20(2):268-277.